Cardiol Therapeutics (CRDL) Return on Capital Employed (2021 - 2026)
Cardiol Therapeutics (CRDL) reported Return on Capital Employed of 175.85% for Q1 2026, up 1334.0% on a YoY basis from 12.26% in Q1 2025, and up 42.69% quarter-over-quarter from 306.86% in Q3 2025.
Cardiol Therapeutics (CRDL) Return on Capital Employed (2021 - 2026) Analysis & Trends
Cardiol Therapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 175.85% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1334.0% year-over-year to 175.85%; the trailing twelve-month figure through Mar 2026 stood at 175.85% (up 1334.0% YoY), and the FY2025 full-year result was 155.56%, down 1043.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 175.85%, up from 306.86% in the prior quarter.
- The five-year high for Return on Capital Employed was 53.99% in Q1 2022, with the low at 306.86% in Q3 2025.
- Historically, Return on Capital Employed has averaged 144.0% across 5 years, with a median of 110.54% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 3482 bps — and 2024, when it plunged 17285 bps.
- Cardiol Therapeutics' Return on Capital Employed stood at 76.03% in 2022, then dropped by 9 bps to 82.79% in 2023, then sank by 209 bps to 255.64% in 2024, then declined by 20 bps to 306.86% in 2025, then surged by 43 bps to 175.85% in 2026.
- The last three Return on Capital Employed figures came in at 175.85% (Q1 2026), 306.86% (Q3 2025), and 267.07% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 6.92% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -1.92% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.85% |
| 10 | Cardiol Therapeutics | 168.37 Mn | 148.19 Mn | - | -175.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175.85% |
| Sep 30, 2025 | -306.86% |
| Jun 30, 2025 | -267.07% |
| Mar 31, 2025 | -189.18% |
| Sep 30, 2024 | -255.64% |
| Jun 30, 2024 | -168.17% |
| Mar 31, 2024 | -132.38% |
| Sep 30, 2023 | -82.79% |
| Jun 30, 2023 | -88.70% |
| Mar 31, 2023 | -80.50% |
| Dec 31, 2022 | -76.03% |
| Sep 30, 2022 | -74.05% |
| Jun 30, 2022 | -64.84% |
| Mar 31, 2022 | -53.99% |
| Dec 31, 2021 | -80.41% |
| Sep 30, 2021 | -108.87% |